AGE-RAGE and AGE cross-link interaction: Important players in the pathogenesis of diabetic kidney disease

Hormone and Metabolic Research

Volumn 37, Issue SUPPL. 1, 2005, Pages

  Jensen, L J N ^a   Ostergaard J ^a   Flyvbjerg, Allan ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

2,3 diaminophenazine; ALT 711; ALT 946; Aminoguanidine; Cross link breakers; CTGF; Diabetic nephropathy; IGF I; LR 90; NF B; OPB 9195; PDGF; PKC; PTB; Pyridoxamine; RAGE Antibody; ROS; sRAGE; TGF ; VEGF

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 2,3 DIAMINOPHENAZINE; ACETAMIDE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTIBODY; ADVANCED GLYCATION END PRODUCT RECEPTOR BLOCKING AGENT; ALAGEBRIUM; ALT 946; AMINOGUANIDINE; ANTIOXIDANT; CELL SURFACE RECEPTOR; GLUCOSE; HYDRAZINE DERIVATIVE; LR 90; N (2 ACETAMIDOETHYL)HYDRAZINOCARBOXIMIDAMIDE; N PHENACETYLTHIAZOLIUM BROMIDE; NEUTRALIZING ANTIBODY; PHENAZINE DERIVATIVE; PHENYL 4,5 DIMETHYLTHIAZOLIUM BROMIDE; PYRIDOXAMINE; RECEPTOR BLOCKING AGENT; SOLUBLE ADVANCED GLYCATION END PRODUCT RECEPTOR; TENILSETAM; THIAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; CROSS LINKING; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG RECEPTOR BINDING; GLUCOSE BLOOD LEVEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECEPTOR BINDING; RECEPTOR BLOCKING; TISSUE DISTRIBUTION;

ANIMALS; DIABETIC NEPHROPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY; RECEPTORS, IMMUNOLOGIC;

EID: 20444491242     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-861360     Document Type: Conference Paper

References (95)

1. Marshall SM. Recent advances in diabetic nephropathy. Postgrad Med J 2004; 80: 624-633
2. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004; 66: 1596-1605
3. Jude EB, Anderson SG, Cruickshank JK, Srivatsa A, Tentolouris N, Chandrasekaran R, Gokal R, Boulton AJ. Natural history and prognostic factors of diabetic nephropathy in type 2 diabetes. QJM 2002; 95: 371-377
4. The Diabetes Control and Complications Trial Study Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 978-986
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853
6. Newton CA, Raskin P, Blood pressure control-effects on diabetic nephropathy progression: how low does blood pressure have to be? Curr Diab Rep 2002; 2: 530-538
7. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004; 25: 971-1010
8. Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001; 38: S100-S106
9. Kalousova M, Zima T, Tesar V, Stipek S, Sulkova S. Advanced glycation end products in clinical nephrology. Kidney Blood Press Res 2004; 27: 18-28
10. Williams ME. New therapies for advanced glycation end product nephrotoxicity: current challenges. Am J Kidney Dis 2003; 41: S42-S47
11. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267: 14987-14997
12. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101
13. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27: 535-542
14. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820
15. Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Calkin AC, Cooper ME, Jandeleit-Dahm KA. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 2004; 15: 2125-2138
16. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11: 1656-1666
17. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, van Ypersoled S, Monnier VM, Witztum JL, Kurokawa K. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997; 100: 2995-3004
18. Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, Tatemichi N, Takei Y. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 1997; 99: 1272-1280
19. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001; 108: 1853-1863
20. Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam BG, Murray-McIntosh RP, Cooper ME. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 1997; 40: 619-628
21. Abel M, Ritthaler U, Zhang Y, Deng Y, Schmidt AM, Greten J, Sernau T, Wahl P, Andrassy K, Ritz E. Expression of receptors for advanced glycosylated end-products in renal disease. Nephrol Dial Transplant 1995; 10: 1662-1667
22. Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, Truong LD, Johnson RJ, Lan HY. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 2004; 18: 176-178
23. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003; 14: 1358-1373
24. Pugliese G, Pricci F, Romeo G, Pugliese F, Mene P, Giannini S, Cresci B, Galli G, Rotella CM, Vlassara H, Di Mario U. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 1997; 46: 1881-1887
25. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108: 261-268
26. Twigg SM, Cao Z, McLennan SV, Burns WC, Brammar G, Forbes JM, Cooper ME. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 2002; 143: 4907-4915
27. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 1991; 174: 931-939
28. Ziyadeh FN, Han DC, Cohen JA, Guo J, Cohen MP. Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-beta system. Kidney Int 1998; 53: 631-638
29. Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M. PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 1995; 48: 111-117
30. Chen S, Cohen MP, Lautenslager GT, Shearman CW, Ziyadeh FN. Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells. Kidney Int 2001; 59: 673-681
31. Cohen MP, Ziyadeh FN, Lautenslager GT, Cohen JA, Shearman CW. Glycated albumin stimulation of PKC-beta activity is linked to increased collagen IV in mesangial cells. Am J Physiol 1999; 276: F684-F690
32. Kim YS, Kim BC, Song CY, Hong HK, Moon KC, Lee HS. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. J Lab Clin Med 2001; 138: 59-68
33. Scivittaro V, Ganz MB, Weiss MF. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol 2000; 278: F676-F683
34. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897
35. Lal MA, Brismar H, Eklof AC, Aperia A. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int 2002; 61: 2006-2014
36. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 2003; 63: 464-473
37. Tsuji H, Iehara N, Masegi T, Imura M, Ohkawa J, Arai H, Ishii K, Kita T, Doi T. Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells. Biochem Biophys Res Commun 1998; 245: 583-588
38. Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 2001; 81: 102-113
39. Li JH, Wang W, Huang XR, Oldfield M, Schmidt AM, Cooper ME, Lan HY. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol 2004; 164: 1389-1397
40. Simm A, Munch G, Seif F, Schenk O, Heidland A, Richter H, Vamvakas S, Schinzel R. Advanced glycation endproducts stimulate the MAP-kinase pathway in tubulus cell line LLC-PK1. FEBS Lett 1997; 410: 481-484
41. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994; 91: 11704-11708
42. Striker LJ, Striker GE. Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrol Dial Transplant 1996; 11 Suppl 5: 62-65
43. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994; 91: 9436-9440
44. Bendayan M. Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetes. Kidney Int 1998; 54: 438-447
45. Shikata K, Makino H, Sugimoto H, Kushiro M, Ota K, Akiyama K, Araki N, Horiuchi S, Ota Z. Localization of advanced glycation endproducts in the kidney of experimental diabetic rats. J Diabetes Compl 1995; 9: 269-271
46. Niwa T, Katsuzaki T, Ishizaki Y, Hayase F, Miyazaki T, Uematsu T, Tatemichi N, Takei Y. Imidazolone, a novel advanced glycation end product, is present at high levels in kidneys of rats with streptozotocin-induced diabetes. FEBS Lett 1997; 407: 297-302
47. Nakamura S, Tachikawa T, Tobita K, Aoyama I, Takayama F, Enomoto A, Niwa T. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats. Am J Kidney Dis 2003; 41: S68-S71
48. Bach LA, Dean R, Youssef S, Cooper ME. Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy. Nephrol Dial Transplant 2000; 15: 347-354
49. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002; 51: 3274-3282
50. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123-1137
51. Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 2002; 18: 224-237
52. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, Ishida M, Ishikawa S, Yasumura K, Koike T. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999; 42: 579-588
53. Rong J, Qiu H, Wang S. Advanced glycosylation end products, protein kinase C and renal alterations in diabetic rats. Chin Med J (Engl) 2000; 113: 1087-1091
54. Adhikary L, Chow F, Nikolic-Paterson DJ, Stambe C, Dowling J, Atkins RC, Tesch GH. Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia 2004; 47: 1210-1222
55. Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, Truong LD, Johnson RJ, Lan HY. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 2004; 18: 176-178
56. Suzuki D, Miyata T, Saotome N, Horie K, Inagi R, Yasuda Y, Uchida K, Izuhara Y, Yagame M, Sakai H, Kurokawa K. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999; 10: 822-832
57. Miyata S, Monnier V. Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal anti-body to pyrraline. J Clin Invest 1992; 89: 1102-1112
58. Garlick RL, Bunn HF, Spiro RG. Nonenzymatic glycation of basement membranes from human glomeruli and bovine sources. Effect of diabetes and age. Diabetes 1988; 37: 1144-1150
59. Berg TJ, Clausen JT, Torjesen PA, Dahl-Jorgensen K, Bangstad HJ, Hanssen KF. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care 1998; 21: 1997-2002
60. Berg TJ, Bangstad HJ, Torjesen PA, Osterby R, Bucala R, Hanssen KF. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 1997; 46: 661-665
61. Schalkwijk CG, Ligtvoet N, Twaalfhoven H, Jager A, Blaauwgeers HG, Schlingemann RO, Tarnow L, Parving HH, Stehouwer CD, van Hinsbergh VW. Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes 1999; 48: 2446-2453
62. Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y. Increased serum levels of advanced glycation end products in NIDDM patients with diabetic complications. Diabetes Care 1998; 21: 1027
63. Kanauchi M, Nishioka H, Dohi K. Serum levels of advanced glycosylation end products in diabetic nephropathy. Nephron 2001; 89: 228-230
64. Wautier MP, Massin P, Guillausseau PJ, Huijberts M, Levy B, Boulanger E, Laloi-Michelin M, Wautier JL. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. (Abstract). Diabetes Metab 2003; 29: 44-52
65. Wagner Z, Wittmann I, Mazak I, Schinzel R, Heidland A, Kientsch-Engel R, Nagy J. N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function. Am J Kidney Dis 2001; 38: 785-791
66. Shibayama R, Araki N, Nagai R, Horiuchi S. Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction. Diabetes 1999; 48: 1842-1849
67. Vay D, Vidali M, Allochis G, Cusaro C, Rolla R, Mottaran E, Bellomo G, Albano E. Antibodies against advanced glycation end product Nepsilon- (carboxymethyl)lysine in healthy controls and diabetic patients. Diabetologia 2000; 43: 1385-1388
68. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997; 94: 6474-6479
69. Pettersson-Fernholm K, Forsblom C, Hudson BI, Perola M, Grant PJ, Groop PH. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 2003; 52: 891-894
70. Poirier O, Nicaud V, Vionnet N, Raoux S, Tarnow L, Vlassara H, Parving HH, Cambien F. Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. Diabetes 2001; 50: 1214-1218
71. Matsunaga-Irie S, Maruyama T, Yamamoto Y, Motohashi Y, Hirose H, Shimada A, Murata M, Saruta T. Relation between development of nephropathy and the p22phox C242T and receptor for advanced glycation end product G 1704T gene polymorphisms in type 2 diabetic patients. Diabetes Care 2004; 27: 303-307
72. Davis BJ, Forbes JM, Thomas MC, Jerums G, Burns WC, Kawachi H, Allen TJ, Cooper ME. Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 2004; 47: 89-97
73. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328-1334
74. Azal O, Yonem A, Guler S, Cakir B, Baydar A, Corakci A, Kutlu M. Effects of aminoguanidine and tolrestat on the development of ocular and renal structural changes in experimental diabetic rats. Diabetes Obes Metab 2002; 4: 75-79
75. Yamauchi A, Takei I, Makita Z, Nakamoto S, Ohashi N, Kiguchi H, Ishii T, Koike T, Saruta T. Effects of aminoguanidine on serum advanced glycation endproducts, urinary albumin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats. Diabetes Res Clin Pract 1997; 34: 127-133
76. Osicka TM, Yu Y, Panagiotopoulos S, Clavant SP, Kiriazis Z, Pike RN, Pratt LM, Russo LM, Kemp BE, Comper WD, Jerums G. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 2000; 49: 87-93
77. Agardh CD, Stenram U, Torffvit O, Agardh E. Effects of inhibition of glycation and oxidative stress on the development of diabetic nephropathy in rats. J Diabetes Compl 2002; 16: 395-400
78. Oturai PS, Rasch R, Hasselager E, Johansen PB, Yokoyama H, Thomsen MK, Myrup B, Kofoed-Enevoldsen A, Deckert T. Effects of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats. APMIS 1996; 104: 259-264
79. Osicka TM, Yu Y, Lee V, Panagiotopoulos S, Kemp BE, Jerums G. Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery. Clin Sci (Lond) 2001; 100: 249-257
80. Huang Y, Lin S, Zhou J. Gene expression of receptor for advanced glycosylation end products and its modulation by aminoguanidine in diabetic kidney tissue. (Abstract). Chin Med J (Engl) 1998; 111: 698-704
81. Booth AA, Khalifah RG, Todd P, Hudson BG. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem 1997; 272: 5430-5437
82. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-950
83. Alderson NL, Chachich ME, Frizzell N, Canning P, Metz TO, Januszewski AS, Youssef NN, Stitt AW, Baynes JW, Thorpe SR. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. Diabetologia 2004; 47: 1385-1395
84. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, Kawata T, Koike T. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997; 46: 895-899
85. Figarola JL, Scott S, Loera S, Tessler C, Chu P, Weiss L, Hardy J, Rahbar S. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 2003; 46: 1140-1152
86. Soulis T, Sastra S, Thallas V, Mortensen SB, Wilken M, Clausen JT, Bjerrum OJ, Petersen H, Lau J, Jerums G, Boel E, Cooper ME. A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Diabetologia 1999; 42: 472-479
87. Oturai PS, Christensen M, Rolin B, Pedersen KE, Mortensen SB, Boel E. Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats. Metabolism 2000; 49: 996-1000
88. Shoda H, Miyata S, Liu BF, Yamada H, Ohara T, Suzuki K, Oimomi M, Kasuga M. Inhibitory effects of tenilsetam on the Maillard reaction. Endocrinology 1997; 138: 1886-1892
89. Flyvbjerg A, Denner L, Schrijvers BF, Tilton RG, Mogensen TH, Paludan SR, Rasch R. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004; 53: 166-172
90. Schwedler SB, Verbeke P, Bakala H, Weiss MF, Vilar J, Depreux P, Fourmaintraux E, Striker LJ, Striker GE. N-phenacylthiazolium bromide decreases renal and increases urinary advanced glycation end products excretion without ameliorating diabetic nephropathy in C57BL/6 mice. Diabetes Obes Metab 2001; 3: 230-239
91. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, Wagle D, Jerums G, Cooper ME. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001;44:108-114
92. Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V, Cooper ME. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 2002; 51: 3283-3289
93. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth JP. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24: 32-40
94. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003; 419: 31-40
95. McGill JB, Williams ME, Degenhardt TP, Szabo JR, Scotzinger RJ. A Phase 2 Clinical Investigation of Pyridoxamine (Pyrdorin) in Type 1 and Type 2 Diabetic Patients with Overt Diabetic Nephropathy (PYR-205/207). (Abstract). J Am Soc Nephrol 2004; 15: 565A